The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Effects of Hydroxychloroquine on Symptomatic Improvement in Primary Sjögren Syndrome: The JOQUER Randomized Clinical Trial
Abstract
IMPORTANCE: Primary Sjögren syndrome is a systemic autoimmune disease characterized by mouth and eye dryness, pain, and fatigue. Hydroxychloroquine is the most frequently prescribed immunosuppressant for the syndrome. However, evidence regarding its efficacy is limited. OBJECTIVE: To evaluate the efficacy of hydroxychloroquine for the main symptoms of primary Sjögren syndrome: dryness, pain, and fatigue. DESIGN, SETTING, AND PARTICIPANTS: From April 2008 to May 2011, 120 patients with primary Sjögren syndrome according to American-European Consensus Group Criteria from 15 university hospitals in France were randomized in a double-blind, parallel-group, placebo-controlled trial. Participants were assessed at baseline, week 12, week 24 (primary outcome), and week 48. The last follow-up date for the last patient was May 15, 2012. INTERVENTIONS: Patients were randomized (1:1) to receive hydroxychloroquine (400 mg/d) or placebo until week 24. All patients were prescribed hydroxychloroquine between weeks 24 and 48. MAIN OUTCOMES AND MEASURES: The primary end point was the proportion of patients with a 30% or greater reduction between weeks 0 and 24 in scores on 2 of 3 numeric analog scales (from 0 [best] to 10 [worst]) evaluating dryness, pain, and fatigue. RESULTS: At 24 weeks, the proportion of patients meeting the primary end point was 17.9% (10/56) in the hydroxychloroquine group and 17.2% (11/64) in the placebo group (odds ratio, 1.01; 95% CI, 0.37-2.78; P = .98). Between weeks 0 and 24, the mean (SD) numeric analog scale score for dryness changed from 6.38 (2.14) to 5.85 (2.57) in the placebo group and 6.53 (1.97) to 6.22 (1.87) in the hydroxychloroquine group. The mean (SD) numeric analog scale score for pain changed from 4.92 (2.94) to 5.08 (2.48) in the placebo group and 5.09 (3.06) to 4.59 (2.90) in the hydroxychloroquine group. The mean (SD) numeric analog scale for fatigue changed from 6.26 (2.27) to 5.72 (2.38) in the placebo group and 6.00 (2.52) to 5.94 (2.40) in the hydroxychloroquine group. All but 1 patient in the hydroxychloroquine group had detectable blood levels of the drug. Hydroxychloroquine had no efficacy in patients with anti-SSA autoantibodies, high IgG levels, or systemic involvement. During the first 24 weeks, there were 2 serious adverse events in the hydroxychloroquine group and 3 in the placebo group; in the last 24 weeks, there were 3 serious adverse events in the hydroxychloroquine group and 4 in the placebo group. CONCLUSIONS AND RELEVANCE: Among patients with primary Sjögren syndrome, the use of hydroxychloroquine compared with placebo did not improve symptoms during 24 weeks of treatment. Further studies are needed to evaluate longer-term outcomes. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT00632866.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Vitali, C., Bombardieri, S., Jonsson, R., Moutsopoulos, H. M., Alexander, E. L., Carsons, S. E., Daniels, T. E., Fox, P. C., Fox, R. I., Kassan, S. S., et al. (2002) · Annals of the Rheumatic Diseases · doi:10.1136/ard.61.6.554 · Cited by 5,299
Seror, R., Ravaud, P., Bowman, S. J., Baron, G., Tzioufas, A., Theander, E., Gottenberg, J.-E., Bootsma, H., Mariette, X., & Vitali, C. (2010) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2009.110619 · Cited by 965
Self-citationMechanism of endosomal TLR inhibition by antimalarial drugs and imidazoquinolines
Kužnik, A., Benčina, M., Švajger, U., Jeras, M., Rozman, B., & Jerala, R. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1000702 · Cited by 606
Seror, R., Ravaud, P., Mariette, X., Bootsma, H., Theander, E., Hansen, A., Ramos-Casals, M., Dörner, T., Bombardieri, S., Hachulla, E., et al. (2011) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2010.143743 · Cited by 576
Self-citationRituximab treatment in patients with primary Sjögren's syndrome: An open‐label phase II study
Pijpe, J., van Imhoff, G. W., Spijkervet, F. K. L., Roodenburg, J. L. N., Wolbink, G. J., Mansour, K., Vissink, A., Kallenberg, C. G. M., & Bootsma, H. (2005) · Arthritis & Rheumatism · doi:10.1002/art.21260 · Cited by 500
Meijer, J. M., Meiners, P. M., Vissink, A., Spijkervet, F. K. L., Abdulahad, W., Kamminga, N., Brouwer, E., Kallenberg, C. G. M., & Bootsma, H. (2010) · Arthritis & Rheumatism · doi:10.1002/art.27314 · Cited by 488
Primary Sjögren Syndrome: Clinical and Immunologic Disease Patterns in a Cohort of 400 Patients
GARCÍA-CARRASCO, M., RAMOS-CASALS, M., ROSAS, J., PALLARÉS, L., CALVO-ALEN, J., CERVERA, R., FONT, J., & INGELMO, M. (2002) · Medicine · doi:10.1097/00005792-200207000-00003 · Cited by 443
Mariette, X., Ravaud, P., Steinfeld, S., Baron, G., Goetz, J., Hachulla, E., Combe, B., Puéchal, X., Pennec, Y., Sauvezie, B., et al. (2004) · Arthritis & Rheumatism · doi:10.1002/art.20146 · Cited by 437
Self-citationTreatment of Primary Sjögren Syndrome With Rituximab: A Randomized Trial
Devauchelle-Pensec, V., Mariette, X., Jousse-Joulin, S., Berthelot, J.-M., Perdriger, A., Puéchal, X., Le Guern, V., Sibilia, J., Gottenberg, J.-E., Chiche, L., et al. (2014) · Annals of Internal Medicine · doi:10.7326/m13-1085 · Cited by 429
Treatment of Primary Sjögren Syndrome: A Systematic Review
Ramos-Casals, M., Tzioufas, A. G., Stone, J. H., Sisó, A., & Bosch, X. (2010) · JAMA · doi:10.1001/jama.2010.1014 · Cited by 381
Ramos-Casals, M., Brito-Zeron, P., Siso-Almirall, A., & Bosch, X. (2012) · BMJ · doi:10.1136/bmj.e3821 · Cited by 372
Mariette, X., Seror, R., Quartuccio, L., Baron, G., Salvin, S., Fabris, M., Desmoulins, F., Nocturne, G., Ravaud, P., & De Vita, S. (2015) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2013-203991 · Cited by 329
Self-citationImprovement of Sjögren's syndrome after two infusions of rituximab (anti‐CD20)
Devauchelle‐Pensec, V., Pennec, Y., Morvan, J., Pers, J., Daridon, C., Jousse‐Joulin, S., Roudaut, A., Jamin, C., Renaudineau, Y., Roué, I. Q., et al. (2007) · Arthritis Care & Research · doi:10.1002/art.22536 · Cited by 315
Self-citationTubach, F., Ravaud, P., Beaton, D., Boers, M., Bombardier, C., Felson, D. T., van der Heijde, D. M. F. M., Wells, G. A., & Dougados, M. (2007) · PubMed · Cited by 233
Self-citationKruize, A. A., Hené, R. J., Kallenberg, C. G., van Bijsterveld, O. P., van der Heide, A., Kater, L., & Bijlsma, J. W. (1993) · Annals of the Rheumatic Diseases · doi:10.1136/ard.52.5.360 · Cited by 226
Gottenberg, J.-E., Cinquetti, G., Larroche, C., Combe, B., Hachulla, E., Meyer, O., Pertuiset, E., Kaplanski, G., Chiche, L., Berthelot, J.-M., et al. (2013) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2012-202293 · Cited by 226
Self-citationTreatment of primary Sjögren's syndrome with hydroxychloroquine: a retrospective, open-label study
Fox, R., Dixon, R., Guarrasi, V, & Krubel, S. (1996) · Lupus · doi:10.1177/0961203396005001081 · Cited by 217
Costedoat-Chalumeau, N., Amoura, Z., Hulot, J.-S., Aymard, G., Leroux, G., Marra, D., Lechat, P., & Piette, J.-C. (2007) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2006.067835 · Cited by 213
Gottenberg, J.-E., Seror, R., Miceli-Richard, C., Benessiano, J., Devauchelle-Pensec, V., Dieude, P., Dubost, J.-J., Fauchais, A.-L., Goeb, V., Hachulla, E., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0059868 · Cited by 186
Self-citationTopical and systemic medications for the treatment of primary Sjögren's syndrome
Ramos-Casals, M., Brito-Zerón, P., Sisó-Almirall, A., Bosch, X., & Tzioufas, A. G. (2012) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2012.53 · Cited by 182
Multifaceted effects of hydroxychloroquine in human disease
Olsen, N. J., Schleich, M. A., & Karp, D. R. (2013) · Seminars in Arthritis and Rheumatism · doi:10.1016/j.semarthrit.2013.01.001 · Cited by 153
Tishler, M., Yaron, I., Shirazi, I., & Yaron, M. (1999) · Annals of the Rheumatic Diseases · doi:10.1136/ard.58.4.253 · Cited by 126
Pathogenesis of Sjögren's syndrome and therapeutic consequences
Mariette, X., & Gottenberg, J. (2010) · Current Opinion in Rheumatology · doi:10.1097/bor.0b013e32833c36c5 · Cited by 93
Self-citationTett, S. E., Cutler, D. J., & Brown, K. (1985) · Journal of Chromatography B Biomedical Sciences and Applications · doi:10.1016/s0378-4347(00)82024-1 · Cited by 67
Bowman, S., Hamburger, J., Richards, A., Barry, R. J., & Rauz, S. (2008) · Lara D. Veeken · doi:10.1093/rheumatology/ken426 · Cited by 66
Cited by
Mariette, X., & Criswell, L. A. (2018) · New England Journal of Medicine · doi:10.1056/nejmcp1702514 · Cited by 947
Self-citationBrito-Zerón, P., Baldini, C., Bootsma, H., Bowman, S. J., Jonsson, R., Mariette, X., Sivils, K., Theander, E., Tzioufas, A., & Ramos-Casals, M. (2016) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2016.47 · Cited by 868
Self-citationEULAR recommendations for the management of Sjogren's syndrome with topical and systemic therapies
Ramos-Casals, M., Brito-Zerón, P., Bombardieri, S., Bootsma, H., De Vita, S., Dörner, T., Fisher, B. A., Gottenberg, J.-E., Hernandez-Molina, G., Kocher, A., et al. (2020) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2019-216114 · Cited by 732
Self-citationRainsford, K. D., Parke, A. L., Clifford-Rashotte, M., & Kean, W. F. (2015) · Inflammopharmacology · doi:10.1007/s10787-015-0239-y · Cited by 543
Al-Bari, M. A. A. (2015) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkv018 · Cited by 467
Metadata
- Authors
- Gottenberg, J.-E., Ravaud, P., Puéchal, X., Le Guern, V., Sibilia, J., Goeb, V., Larroche, C., Dubost, J.-J., Rist, S., Saraux, A., Devauchelle-Pensec, V., Morel, J., Hayem, G., Hatron, P., Perdriger, A., Sene, D., Zarnitsky, C., Batouche, D., Furlan, V., Benessiano, J., Perrodeau, E., Seror, R., & Mariette, X.
- Venue
- JAMA
- Publisher
- American Medical Association (AMA)
- Published
- 2014-07-16
- Volume
- 312
- Issue
- 3
- Pages
- 249
- ISSN
- 0002-9955 (ISSN-L)
- 0098-7484
- OpenAlex
- W2034064057
- Cited by
- 311
- References
- 25
- FWCI
- 14.38
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.